EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE

Ramazan Çakmak; Golpouneh Alizad Oghyanous; Özlem Soyluk Selçukbiricik; Kubilay Karşıdağ

Makale detayları

EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE

Yazarlar:

Ramazan Çakmak | Golpouneh Alizad Oghyanous | Özlem Soyluk Selçukbiricik | Kubilay Karşıdağ

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.88 Issue 1, pp.45-52

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001341396

pISSN:

1305-6441

Anahtar kelimeler:

Özet:

 Objective: Sodium-glucose transporter-2 SGLT-2 inhibitors lower blood glucose levels by reducing renal glucose reabsorption without affecting insulin secretion. The aim of our study was to evaluate the effect of SGLT-2 inhibitor treatment on glycemic control and the possible superiority of the drugs by comparing clinical parameters and laboratory findings in Type 2 diabetes mellitus T2DM patients. Material and Methods: Two hundred and nineteen T2DM patients who received SGLT-2 inhibitor therapy empagliflozin EMPA n146 or dapagliflozin DAPA n7310 mg were enrolled retrospectively. The patients demographic characteristics, detailed medical history, comorbidities, physical examination findings, complications, weight and systolic-diastolic blood pressure follow-up, laboratory findings at baseline, 3rd, and 12th month, and overall follow-up outcomes were evaluated. Result: The mean values of HbA1c and fasting blood glucose FBG decreased significantly compared with the baseline values after the treatment. The mean body weight and uric acid values were significantly reduced in the 3rd month of the treatment. Similarly, the values of the liver function tests decreased substantially after treatment. Conclusion: The beneficial effects of SGLT-2 inhibitors on glycemic control and liver functions in patients with T2DM have been demonstrated. In addition, there was no major difference in terms of clinical parameters, laboratory findings, and drug safety in patients between EMPA and DAPA.

 Objective: Sodium-glucose transporter-2 SGLT-2 inhibitors lower blood glucose levels by reducing renal glucose reabsorption without affecting insulin secretion. The aim of our study was to evaluate the effect of SGLT-2 inhibitor treatment on glycemic control and the possible superiority of the drugs by comparing clinical parameters and laboratory findings in Type 2 diabetes mellitus T2DM patients. Material and Methods: Two hundred and nineteen T2DM patients who received SGLT-2 inhibitor therapy empagliflozin EMPA n146 or dapagliflozin DAPA n7310 mg were enrolled retrospectively. The patients demographic characteristics, detailed medical history, comorbidities, physical examination findings, complications, weight and systolic-diastolic blood pressure follow-up, laboratory findings at baseline, 3rd, and 12th month, and overall follow-up outcomes were evaluated. Result: The mean values of HbA1c and fasting blood glucose FBG decreased significantly compared with the baseline values after the treatment. The mean body weight and uric acid values were significantly reduced in the 3rd month of the treatment. Similarly, the values of the liver function tests decreased substantially after treatment. Conclusion: The beneficial effects of SGLT-2 inhibitors on glycemic control and liver functions in patients with T2DM have been demonstrated. In addition, there was no major difference in terms of clinical parameters, laboratory findings, and drug safety in patients between EMPA and DAPA.

 Objective: Sodium-glucose transporter-2 SGLT-2 inhibitors lower blood glucose levels by reducing renal glucose reabsorption without affecting insulin secretion. The aim of our study was to evaluate the effect of SGLT-2 inhibitor treatment on glycemic control and the possible superiority of the drugs by comparing clinical parameters and laboratory findings in Type 2 diabetes mellitus T2DM patients. Material and Methods: Two hundred and nineteen T2DM patients who received SGLT-2 inhibitor therapy empagliflozin EMPA n146 or dapagliflozin DAPA n7310 mg were enrolled retrospectively. The patients demographic characteristics, detailed medical history, comorbidities, physical examination findings, complications, weight and systolic-diastolic blood pressure follow-up, laboratory findings at baseline, 3rd, and 12th month, and overall follow-up outcomes were evaluated. Result: The mean values of HbA1c and fasting blood glucose FBG decreased significantly compared with the baseline values after the treatment. The mean body weight and uric acid values were significantly reduced in the 3rd month of the treatment. Similarly, the values of the liver function tests decreased substantially after treatment. Conclusion: The beneficial effects of SGLT-2 inhibitors on glycemic control and liver functions in patients with T2DM have been demonstrated. In addition, there was no major difference in terms of clinical parameters, laboratory findings, and drug safety in patients between EMPA and DAPA.

 Amaç: Sodyum-glukoz taşıyıcı-2 SGLT-2 inhibitörleri, insülin sekresyonunu etkilemeden renal glukoz reabsorpsiyonunu azaltarak kan glukozunu düşürür. Çalışmamızın amacı, Tip 2 diabetes mellituslu T2DM hastalarda SGLT-2 inhibitör tedavisinin glisemik kontrol üzerindeki etkisini ve ilaçların olası üstünlüklerini klinik parametreler ve laboratuvar bulguları ile karşılaştırarak değerlendirmektir. Gereç ve Yöntem: SGLT-2 inhibitörü tedavisi empagliflozin EMPA n146 veya dapagliflozin DAPA n7310 mg alan 219 T2DM hastalarının verileri geriye dönük olarak kaydedildi. Demografik özellikler, detaylı tıbbi öykü, komorbiditeler, komplikasyonlar, vücut ağırlığı ve kan basıncı takibi, laboratuvar bulguları başlangıçta, 3. ve 12. aylarda incelendi. Bulgular: Bu çalışmamızda SGLT-2 tedavisinden sonra ortalama HbA1c ve açlık plazma glukoz değerleri başlangıç değerlerine göre anlamlı oranda azaldı. Ortalama vücut ağırlığı ve ürik asit değerleri tedavinin 3. ayında anlamlı oranda azaldı. Benzer şekilde karaciğer fonksiyon testleri değerlerinde de tedavi sonrası iyileşmeler görüldü. Sonuç: SGLT-2 inhibitörlerinin T2DM hastalarında glisemik kontrol ve karaciğer fonksiyonu üzerindeki olumlu etkileri açıkça gösterilmiştir. Ayrıca klinik parametreler, laboratuvar bulguları ve ilaç güvenliği açısından EMPA ve DAPA arasında önemli bir fark saptanmamıştır.

Makale detayları

EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE

Yazarlar:

Ramazan Çakmak | Golpouneh Alizad Oghyanous | Özlem Soyluk Selçukbiricik | Kubilay Karşıdağ

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.88 Issue 1, pp.45-52

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001341396

pISSN:

1305-6441

Type 2 diabetes mellitus

sodium-glucose cotransporters

empagliflozin

dapagliflozinTip 2 diabetes mellitüs

sodyum glukoz kotransporterlar

empagliflozin

dapagliflozin

Sayı

Makale detayları

Yazarlar: Ramazan Çakmak | Golpouneh Alizad Oghyanous | Özlem Soyluk Selçukbiricik | Kubilay Karşıdağ

Yayıncı: Istanbul University

Ana Başlıklar: Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi: İstanbul Tıp Fakültesi Dergisi Vol.88 Issue 1, pp.45-52

Belge Tipi: Makale

Yayın Tarihi: 1/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001341396

pISSN: 1305-6441

Sayı

Yazarlar:

Ramazan Çakmak | Golpouneh Alizad Oghyanous | Özlem Soyluk Selçukbiricik | Kubilay Karşıdağ

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.88 Issue 1, pp.45-52

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001341396

pISSN:

1305-6441